COMMUNIQUÉS West-GlobeNewswire

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
02/07/2024
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “ [...]
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
02/07/2024
Dahan brings over two decades of experience in the life sciences industry transforming companies from early pre-clinical stage development to successful product launch and commercialization. Alkeus intends to submit a [...]
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
02/07/2024
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel ( [...]
Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
02/07/2024
TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of [...]
Smart for Life to Attend IFT FIRST Annual Event and Expo in Chicago
02/07/2024
Company Aims to Forge Strategic Partnerships and Explore Acquisition Opportunities at Leading Food Science Event MIAMI, July 02, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “ [...]
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
02/07/2024
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic [...]
Mainz Biomed Provides Half Year 2024 Corporate Update
02/07/2024
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics [...]
Spectral AI Achieves 100% Pediatric Enrollment in Burn Centers for Pivotal U.S. Burn Study
02/07/2024
DALLAS, July 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
01/07/2024
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV) HOOKIPA [...]
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01/07/2024
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Goodness Growth Holdings Announces Name Change to Vireo Growth Inc.
01/07/2024
– Subordinate voting shares expected to begin trading under new ticker symbols on July 8, 2024 – –Ticker symbol “VREO” on the CSE in Canada (CSE: VREO); “VREOF” on OTCQX Market (OTCQX: VREOF) – MINNEAPOLIS, July 01, [...]
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
01/07/2024
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for [...]
AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
01/07/2024
Donna Shiroma retires after distinguished service as General Counsel VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company [...]
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
01/07/2024
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
01/07/2024
LAUSANNE, Switzerland, July 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 172,400 of the Company’s common shares to [...]
Stryker to announce financial results for its second quarter of fiscal year 2024
01/07/2024
Portage, Michigan, July 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, July 30, 2024. A press release will be issued at [...]
Nexalin Technology Announces Closing of $5.2 Million Public Offering
01/07/2024
HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of 3,000,000 shares of [...]
A-S Medication Solutions Announces Strategic Transition
01/07/2024
LIBERTYVILLE, Ill., July 01, 2024 (GLOBE NEWSWIRE) -- A-S Medication Solutions (ASM) today announced a strategic transition of its relationship with Triple Aim Consulting, LLC (“TAC”). For a number of years, ASM has had [...]
BioPorto confirms market acceptance of NGAL products with US standing order.
01/07/2024
July 1, 2024 News Release BioPorto confirms market acceptance of NGAL products with US standing order. COPENHAGEN, Denmark and BOSTON, MA, USA, July 1, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH: [...]

Pages